ZBIOZenas BioPharma, Inc.vs its industry peers
A metric-by-metric comparison of Zenas BioPharma, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZBIOEsta | $1.9B#5 | — | 7.6x#2 | 188.2x#4 | 100.0%#2 | -140.6%#5 | -3830.6%#5 | -152.9%#4 | -296.6%#4 | — | -7.6%#4 | — |
| PRGO | $2.2B#1 | — | 0.9x#1 | 0.5x#1 | -2.8%#5 | -729.7%#6 | -26.4%#2 | -56.7%#2 | -20.9%#2 | 4#1 | -18.1%#5 | 7.3%#1 |
| ZYME | $2.2B#2 | — | 26.8x#4 | 20.3x#3 | 38.9%#4 | 33.9%#2 | -87.3%#3 | -100.9%#3 | — | — | 60.5%#1 | — |
| BRVE | $1.9B#3 | — | — | — | — | — | — | — | — | — | — | — |
| XERS | $1.9B#4 | — | — | 6.5x#2 | 43.7%#3 | 101.0%#1 | 8.5%#1 | — | 20.6%#1 | — | 5.6%#3 | — |
| PGEN | $1.9B#6 | — | 42.5x#5 | 191.3x#5 | 146.7%#1 | -98.6%#4 | -1141.1%#4 | -575.1%#5 | -91.2%#3 | — | 24.5%#2 | — |
| SLS | $1.8B#7 | — | 12.9x#3 | — | -100.0%#6 | 13.0%#3 | — | -19.5%#1 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice